Navigation Links
LSUHSC'S OCHOA 1 of 10 chosen by NIH director for Transformative Research Award
Date:10/1/2013

New Orleans, LA Dr. Augusto Ochoa, Director of the Stanley S. Scott Cancer Center and Al Copeland/Cancer Crusaders Chair in Neuroendocrine Cancer at LSU Health Sciences Center New Orleans, has been selected as one of ten recipients nationally of the 2013 National Institutes of Health Transformative Research Award. Awarded by NIH Director Dr. Francis Collins, the award comes with a $2.5 million grant over five years to LSUHSC to support the development of new treatments for severe viral diseases, including herpes infections, pandemic influenza and cancers caused viruses, by manipulating how the immune system responds to severe viral and inflammatory infections.

According to the NIH, the NIH Director's Transformative Research Award initiative was created specifically to support exceptionally innovative, groundbreaking, high risk, original, and/or unconventional research projects that have the potential to create or overturn fundamental scientific paradigms. Funded by the NIH Common Fund, projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or behavioral research. The other recipients are from such places as Harvard, Stanford, and MIT. Dr. Ochoa is the only recipient in Louisiana.

Severe viral diseases, such as infections of the eye and brain caused by herpes viruses, influenza, and certain cancers, are caused by a combination of direct initial damage to the cells by the virus and damage from severe and chronic inflammation resulting from the body's fight against the infection. These diseases are difficult to treat and can cause long-lasting complications, disabilities, and sometimes even death.

Preliminary LSUHSC research on Herpes keratitis, a severe eye infection caused by herpes simplex virus 1 (HSV1) and the most frequent cause of blindness by a infectious agent in developed countries, shows great promise. The LSUHSC research team discovered that a substance produced by the immune system not only kills the virus, but also controls the damaging inflammation that accompanies this disease.

"It is important to find a treatment that can both kill the virus and control inflammation while allowing for the development of protective and long-lasting immunity," notes Dr. Augusto Ochoa, Director of the Stanley S. Scott Cancer Center and Al Copeland/Cancer Crusaders Chair in Neuroendocrine Cancer at LSU Health Sciences Center New Orleans. "Our work suggests that simple and achievable metabolic changes can provide both of these effects and promote the healing of the tissues by altering the way the body responds to viral infections."

The grant will fund a research team including LSUHSC's Dr. Ochoa and Dr. Paulo Rodriguez, leaders in the field of immunology, chronic inflammation and immunotherapy, and Dr. James Hill and Dr. Timothy Foster, experts in ophthalmology and virology, as well as scientists with expertise in cancer immunotherapies and pulmonary infections from the Medical College of Georgia and the University of Tennessee.

Additionally, this award will create two new postdoctoral positions at LSUHSC and will support the training and mentorship of junior scientists, postdoctoral fellows, and graduate students.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Practicing Sustainability chosen for a silver Nautilus Book Award
2. LSUHSCs Weiss chosen to help set national eye policy, research
3. GW Research chosen as paper of the week for blood coagulation discovery
4. University of Utah researchers receive NIH Directors New Innovator Award
5. Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference
6. DARPA director: Revolutionary weapons require strong S&T partnerships
7. Stanford bioengineer Christina Smolke wins NIH Directors Pioneer Award
8. George Washington University Computational Biology Director solves 200-year-old oceanic mystery
9. BiOptix announces expansion of Board of Directors
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. $1.5 million NCI Grant to aid Huntsman Cancer Institute researcher study melanoma, sun damage link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: